One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Daniel Porte Jr, 13 August 1931–13 May 2023
Steven E. Kahn & Michael W. Schwartz
Incretins: turning the venom into the antidote
Anna Krook & Hindrik Mulder
The expanding incretin universe: from basic biology to clinical translation
Daniel J. Drucker & Jens J. Holst
Incretin hormones and type 2 diabetes
Michael A. Nauck & Timo D. Müller
Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy
Matthias Tschöp, Ruben Nogueiras & Bo Ahrén
Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Anna Solini, Domenico Tricò & Stefano Del Prato
Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy
Jonathan Goldney, Jack A. Sargeant & Melanie J. Davies
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Christine R. Andreasen, Andreas Andersen & Tina Vilsbøll
Socioeconomic aspects of incretin-based therapy
Thomas Karagiannis, Eleni Bekiari & Apostolos Tsapas
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
Matthew Anson, Sizheng S. Zhao, Philip Austin, Gema H. Ibarburu, Rayaz A. Malik & Uazman Alam
Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial
Anupam Garrib, Sokoine Kivuyo, Katie Bates, Kaushik Ramaiya, Duolao Wang, Edna Majaliwa, Rehema Simbauranga, Godbless Charles, Erik van Widenfelt, Huanyan Luo, Uazman Alam, Moffat J. Nyirenda, Shabbar Jaffar & Sayoki Mfinanga on behalf of the META trial team
Strength training is more effective than aerobic exercise for improving glycaemic control and body composition in people with normal-weight type 2 diabetes: a randomised controlled trial
Yukari Kobayashi, Jin Long, Shozen Dan, Neil M. Johannsen, Ruth Talamoa, Sonia Raghuram, Sukyung Chung, Kyla Kent, Marina Basina, Cynthia Lamendola, Francois Haddad, Mary B. Leonard, Timothy S. Church & Latha Palaniappan
Glycaemic control, risk of hypoglycaemia and all-cause mortality in new users of second-generation basal insulin with type 2 diabetes and chronic kidney disease: a nationwide register-based cohort study
Vanja Kosjerina, Bendix Carstensen, Hanan Amadid & Dorte Vistisen
Genetic associations vary across the spectrum of fasting serum insulin: results from the European IDEFICS/I.Family children’s cohort
Kirsten Mehlig, Ronja Foraita, Rajini Nagrani, Marvin N. Wright, Stefaan De Henauw, Dénes Molnár, Luis A. Moreno, Paola Russo, Michael Tornaritis, Toomas Veidebaum, Lauren Lissner, Jaakko Kaprio & Iris Pigeot on behalf of the I.Family consortium
Hyperglucagonaemia in diabetes: altered amino acid metabolism triggers mTORC1 activation, which drives glucagon production
Yael Riahi, Aviram Kogot-Levin, Liat Kadosh, Bella Agranovich, Assaf Malka, Michael Assa, Ron Piran, Dana Avrahami, Benjamin Glaser, Eyal Gottlieb, Fields Jackson III, Erol Cerasi, Ernesto Bernal-Mizrachi, Aharon Helman & Gil Leibowitz
Reversal of dual epigenetic repression of non-canonical Wnt-5a normalises diabetic corneal epithelial wound healing and stem cells
Ruchi Shah, Tanya M. Spektor, Daniel J. Weisenberger, Hui Ding, Rameshwar Patil, Cynthia Amador, Xue-Ying Song, Steven T. Chun, Jake Inzalaco, Sue Turjman, Sean Ghiam, Jiho Jeong-Kim, Sasha Tolstoff, Sabina V. Yampolsky, Onkar B. Sawant, Yaron S. Rabinowitz, Ezra Maguen, Pedram Hamrah, Clive N. Svendsen, Mehrnoosh Saghizadeh, Julia Y. Ljubimova, Andrei A. Kramerov & Alexander V. Ljubimov
